secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-199158
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA
--------------------------------------------------------------------------------

- Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.
- ARCHER Phase 2 trial in geographic atrophy showed ANX007 provided dose-dependent, statistically significant protection from vision loss (BCVA ≥15 letters).
- Primary endpoint of GA lesion growth rate did not reach significance; additional analyses show trend toward greater effect in second six months.
- ANX007 was well-tolerated with no increase in CNV or retinal vasculitis; company to discuss regulatory path with FDA later this year.
- Fellow-eye analysis showed 74% (monthly) and 47% (every-other-month) reduction in BCVA loss vs sham; off-treatment data support on-treatment benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/0001193125-23-199158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/d418528d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-199158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer